Pharmaceutical company Organon has licensed Spotfire’s DecisionSite software to accelerate the progression of drugs from its research pipeline to clinical development.
Organon intends to use the software to improve communication and collaboration between scientists in the different stages of the discovery process. It will encourage its employees to share data and knowledge at earlier stages of the development process and so more accurately predict drug effects in humans at a much earlier phase.
Organon believes that by providing retrievable, analysis-ready data across the R&D pipeline, it can better detect early-warning indications that reduce costly late-stage failures, while at the same time, bringing quality compounds to market faster.
Spotfire’s analytic capabilities introduce a new way for our researchers to exchange and analyze complex data across the R&D organization, said David Nicholson, EVP global research and development at Organon.
DecisionSite provides an interactive, analytical environment that supports a new approach to integrated drug-design and discovery – optimizing early drug candidates and leading to a reduction in late-stage failures.